Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB-1003
- Development stage
- Preclinical
- Lead developer
- IMIDomics
- Modality
- Recombinant Proteins and Enzymes
01
Overview
IMB-1003 is a protein-based drug candidate developed by Imidomics for the treatment of immune-mediated inflammatory diseases (IMIDs), including autoimmune disorders. The drug is being advanced through a collaboration between Imidomics and the University of Barcelona, leveraging proprietary technology and expertise in biologics discovery. IMB-1003 is currently in preclinical development, with primary indications targeting Crohn disease and systemic lupus erythematosus. The mechanism of action has not been publicly disclosed, but it is part of a new generation of therapies aimed at modulating immune system activity to address severe, debilitating conditions that currently lack effective treatments[1][3][4].
Beyond the preview
Go deeper on IMB-1003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB-1003.